Media Type: eBook
Availability: In stock
In the past, systemic immunomodulation therapy (IMT) was used almost exclusively for cases refractory to corticosteroids, but now IMT is routinely implemented for a wide range of ophthalmic diseases. Evidence from multiple studies has demonstrated that patients with certain autoimmune ophthalmic diseases have better prognoses when IMT is used concomitantly with corticosteroids.
This Focal Points module highlights how the use of IMT has become the standard of care for most sight-threatening autoimmune ophthalmic disorders. Additionally, the safety profile of IMT medications has been adequately established, and in most cases, their use is justified, given the blinding potential of most underlying conditions.
By completing this module, you will be able to:
Authors: Ahmed B. Sallam, MD, PhD and Armando L. Oliver, MD
Focal Points issues review the most crucial advances and feature insights to help you integrate tested findings into your practice.
Subscribers receive 12 issues a year, plus access to the Focal Points digital archive.
This issue includes an audio version. To access the audio version of this module, scan the QR code in the print module or click the link within the digital module.
To access this issue from your laptop or desktop computer, log in to aao.org/myonlineproducts with your Academy username and password.
To access this issue from your smartphone or tablet, use the free AAO eBooks app. For eBook features, requirements and licensing, visit: aao.org/ebooks. Please allow up to 90 minutes for receiving an access key (via email) that will allow you to retrieve your eBook after purchase.
The American Academy of Ophthalmology is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The American Academy of Ophthalmology designates this enduring material for a maximum of 2 AMA PRA Category 1 Credits™.